
|Articles|January 30, 2014
DS Healthcare Chooses Aptiv Solutions as Its CRO
DS Healthcare Group, Inc announced it has appointed Aptiv Solutions as CRO for its proprietary topical prescription treatment.
Advertisement
Aptiv Solutions, as DS Healthcare's CRO, will prepare the company's Investigational New Drug Application (IND) for its proprietary topical hair loss treatment, for submission to the FDA. To date, only one other topical treatment for hair loss has been approved by the FDA. Aptiv Solutions will also conduct a Gap analysis to ensure that DS Healthcare's operations are in line with regulatory requirements for drug approval.
You can read the full release
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Real-Time Trials Need More Than AI: Why Operational Trial Infrastructure Matters
2
Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies
3
ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma
4
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
5



